MedTrace Logo

A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

NCT05574114 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-11-04

No results posted yet for this study

Summary

The purpose of this study is to test whether radiation therapy given before standard CAR T cell therapy is a safe and effective treatment for people with relapsed and refractory B cell lymphoma. The researchers will also study whether radiation therapy used in this study is a practical treatment option before standard CAR T cell therapy.

Conditions

Interventions

RADIATION

Bridging radiotherapy (BRT)

RT Part I. The target will be to complete the 9th fraction of radiotherapy (i.e., total of 27Gy) between days -12 and -8 Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy).

DRUG

Conditioning chemotherapy

Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy

BIOLOGICAL

CAR T-cell product

Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product.

Sponsors & Collaborators

Principal Investigators

  • Lia Palomba, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-05
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05574114 on ClinicalTrials.gov